from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. dimebolin


Sorry, no etymologies found.


  • The job cuts come three weeks after data from the 598-patient CONNECTION trial which showed that Dimebon (latrepirdine), which is partnered with Pfizer, did not meet its co-primary or secondary efficacy endpoints compared to placebo.

    PharmaTimes World News

  • An early stage clinical trial of the experimental drug dimebon (latrepirdine) in people with Huntington's disease appears to be safe and may improve cognition.

    Science Blog

  • The two companies are testing Dimebon, known chemically as latrepirdine, in three additional studies involving patients with moderate to severe Alzheimer's, and in one involving patients with Huntington's disease.

    Latest News

  • In September 2008, Medivation announced a global agreement with Pfizer, Inc to develop and commercialize dimebon (latrepirdine) for the treatment of Alzheimer's and Huntington diseases.

    RedOrbit News - Technology

  • Dimebon (latrepirdine), a pill being developed for Alzheimer's disease, has been found to improve mental abilities in some patients with Huntington's disease, says a new study.

    Medindia Health News

  • The Company's product pipeline includes Dimebon - also known by its generic name, latrepirdine - a drug being developed as a treatment for mild-to-moderate Alzheimer's disease. News Articles

  • Feb 9 (ANI): Dimebon (latrepirdine), a pill being developed for Alzheimer's mental abilities in some patients with Huntington's ... - Articles related to Keys to Better Sleep

  • Newswise - A medication previously studied in patients with Alzheimer's disease (proposed generic name = latrepirdine) appears well tolerated and may improve thinking, learning and memory skills among individuals with Huntington's disease, according to a report in the February issue of

    Newswise: Latest News

  • "Future studies of latrepirdine are planned to further evaluate the effect of latrepirdine on the cognitive and behavioral symptoms of Huntington's disease."

    Newswise: Latest News

  • "Taken together, our data suggest that latrepirdine, at a dosage of 20 milligrams three times daily, is well tolerated for 90 days in patients with Huntington's disease and may have a beneficial effect on cognition," the authors conclude.

    Newswise: Latest News


Log in or sign up to get involved in the conversation. It's quick and easy.